<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment protocols for esophagogastric cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment protocols for esophagogastric cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment protocols for esophagogastric cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tim Brenner, PharmD, BCOP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shrina Duggal, PharmD, BCOP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jim Natale, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H15190182"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with esophageal and gastric cancer, both in the adjuvant/neoadjuvant setting and for advanced disease. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with esophagogastric cancer. Additional regimens may be added over time, particularly as treatment for esophagogastric cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with esophagogastric cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2523.html" rel="external">"Adjuvant and neoadjuvant treatment of gastric cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">"Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer"</a>.)</p><p></p><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class="headingAnchor" id="H15190339"><span class="h1">REGIMENS</span></p><p class="headingAnchor" id="H15196435"><span class="h2">Chemotherapy alone</span></p><p class="headingAnchor" id="H4277333127"><span class="h3">Adjuvant capecitabine plus oxaliplatin (CAPOX) for stage II to III gastric cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef114120" href="/z/d/graphic/114120.html" rel="external">table 1</a>)</p><p class="headingAnchor" id="H761957244"><span class="h3">Capecitabine plus oxaliplatin advanced esophagogastric cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef112347" href="/z/d/graphic/112347.html" rel="external">table 2</a>)</p><p class="headingAnchor" id="H933416664"><span class="h3">Docetaxel, cisplatin, and fluorouracil (DCF)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef73324" href="/z/d/graphic/73324.html" rel="external">table 3</a>)</p><p class="headingAnchor" id="H15190442"><span class="h3">Modified docetaxel, cisplatin, and fluorouracil (modified DCF)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef79612" href="/z/d/graphic/79612.html" rel="external">table 4</a>)</p><p class="headingAnchor" id="H933416689"><span class="h3">Epirubicin, cisplatin, and fluorouracil (ECF)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef62502" href="/z/d/graphic/62502.html" rel="external">table 5</a>)</p><p class="headingAnchor" id="H933416714"><span class="h3">Epirubicin, cisplatin, and capecitabine (ECX)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef53899" href="/z/d/graphic/53899.html" rel="external">table 6</a>)</p><p class="headingAnchor" id="H933416739"><span class="h3">Epirubicin, oxaliplatin, and capecitabine (EOX)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef75288" href="/z/d/graphic/75288.html" rel="external">table 7</a>)</p><p class="headingAnchor" id="H2020817766"><span class="h3">Perioperative docetaxel, oxaliplatin, fluorouracil, and leucovorin (FLOT4)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef120512" href="/z/d/graphic/120512.html" rel="external">table 8</a>) </p><p class="headingAnchor" id="H933416764"><span class="h3">FOLFIRI (fluorouracil plus leucovorin and irinotecan)</span><span class="headingEndMark"> — </span>Although the published experience in advanced esophagogastric cancer is with slightly different regimens, most clinicians use the same FOLFIRI regimen as is used for advanced colorectal cancer  (<a class="graphic graphic_table graphicRef76300" href="/z/d/graphic/76300.html" rel="external">table 9</a>). (See  <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">"Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer", section on 'Irinotecan-containing regimens'</a>.)</p><p class="headingAnchor" id="H933416821"><span class="h3">Irinotecan plus cisplatin</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef62115" href="/z/d/graphic/62115.html" rel="external">table 10</a>)</p><p class="headingAnchor" id="H933416793"><span class="h3">Modified FOLFOX6 and modified FOLFOX7 (fluorouracil plus leucovorin and oxaliplatin)</span><span class="headingEndMark"> — </span>Although the published experience in advanced esophagogastric cancer is with slightly different regimens, most clinicians use the same modified FOLFOX6 and FOLFOX7 regimens as are used for colorectal cancer  (<a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">table 11</a> and <a class="graphic graphic_table graphicRef55829" href="/z/d/graphic/55829.html" rel="external">table 12</a>). (See  <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">"Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer", section on 'Oxaliplatin combinations'</a>.)</p><p class="headingAnchor" id="H273135266"><span class="h3">Ramucirumab plus paclitaxel for advanced esophagogastric adenocarcinoma</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef132475" href="/z/d/graphic/132475.html" rel="external">table 13</a>)</p><p class="headingAnchor" id="H1108924261"><span class="h3">Single-agent ramucirumab for advanced esophagogastric adenocarcinoma</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef132474" href="/z/d/graphic/132474.html" rel="external">table 14</a>)</p><p class="headingAnchor" id="H958003"><span class="h3">Trastuzumab-containing regimens for HER2-positive advanced adenocarcinomas</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/2473.html" rel="external">"Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer", section on 'HER2-overexpressing adenocarcinomas'</a>.)</p><p class="headingAnchor" id="H1121265809"><span class="h4">Trastuzumab plus capecitabine and cisplatin</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef86570" href="/z/d/graphic/86570.html" rel="external">table 15</a>)</p><p class="headingAnchor" id="H1347756028"><span class="h4">Trastuzumab plus fluorouracil and cisplatin</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef86571" href="/z/d/graphic/86571.html" rel="external">table 16</a>)</p><p class="headingAnchor" id="H708996723"><span class="h4">FOLFOX plus trastuzumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef109416" href="/z/d/graphic/109416.html" rel="external">table 17</a>)</p><p class="headingAnchor" id="H604694817"><span class="h4">Capecitabine and oxaliplatin (CAPOX) plus trastuzumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef109415" href="/z/d/graphic/109415.html" rel="external">table 18</a>)</p><p class="headingAnchor" id="H15196507"><span class="h2">Concurrent chemoradiotherapy</span></p><p class="headingAnchor" id="H933416871"><span class="h3">Weekly carboplatin plus paclitaxel with concurrent radiotherapy</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef68266" href="/z/d/graphic/68266.html" rel="external">table 19</a>)</p><p class="headingAnchor" id="H20092197"><span class="h3">Trimodality therapy with cisplatin plus fluorouracil and concurrent radiotherapy followed by surgery</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef87313" href="/z/d/graphic/87313.html" rel="external">table 20</a>)</p><p class="headingAnchor" id="H2951966225"><span class="h2">Immunotherapy</span></p><p class="headingAnchor" id="H1234897315"><span class="h3">Pembrolizumab monotherapy for PD-L1-overexpressing or microsatellite-unstable (mismatch repair-deficient) advanced cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 21</a>)</p><p class="headingAnchor" id="H3436924712"><span class="h3">Adjuvant nivolumab for resected esophageal or gastroesophageal cancer</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef131676" href="/z/d/graphic/131676.html" rel="external">table 22</a>)</p><p class="headingAnchor" id="H3437385100"><span class="h2">Systemic therapy</span></p><p class="headingAnchor" id="H2795009042"><span class="h3">Pembrolizumab plus FOLFOX and trastuzumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef141603" href="/z/d/graphic/141603.html" rel="external">table 23</a>)</p><p class="headingAnchor" id="H2549948632"><span class="h3">Pembrolizumab plus CAPOX (capecitabine and oxaliplatin) and trastuzumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef141602" href="/z/d/graphic/141602.html" rel="external">table 24</a>)</p><p class="headingAnchor" id="H2211148457"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.</p></div><div id="topicVersionRevision">Topic 85680 Version 30.0</div></div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
